Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The 2020 ACR Review Course: Key Issues Rheumatologists Face

Jason Liebowitz, MD, FACR  |  Issue: January 2021  |  December 17, 2020

Osteoporosis Update
Next, Abby Abelson, MD, chair of the Department of Rheumatic and Immunologic Diseases at the Cleveland Clinic, provided an update on osteoporosis. Dr. Abelson noted that 80% of individuals who have had at least one osteoporotic fracture are neither identified nor treated for osteoporosis and that the percentage increase in hip fractures from 1990 to 2050 is projected to be 240% in women and 310% in men.8

Much of her talk was spent discussing romosozumab, the newest osteoporosis medication on the market, which was approved for treatment of post-menopausal osteoporosis in 2019. In the FRAME study, more than 7,000 post-menopausal women with a T-score between -2.5 and -3.5 were randomized to receive 210 mg of romosozumab via subcutaneous injection monthly for 12 months or placebo, with both groups then treated with denosumab 60 mg via subcutaneous injection every six months for 12 months. This study showed that romosozumab was associated with a lower risk of vertebral fracture than placebo at 12 months and, after the transition to denosumab, at 24 months as well.9

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

 In the ARCH trial, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone for post-menopausal women at high risk for fracture.10 Together, these studies indicate the important foundational effect of romosozumab, meaning that treatment with this agent followed by treatment with another agent may provide important gains in bone mass and lower long-term risk of fracture.

Dr. Abelson noted that, given the potential for increased major adverse cardiovascular events with romosozumab treatment, it is unclear how far out from such events as stroke or myocardial infarction patients should be before considering this treatment. Other issues with romosozumab are that it is limited to women—fracture studies in men have not yet been conducted—and the monthly visits required for treatment may be challenging in the midst of the current COVID-19 pandemic.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The speakers in the Review Course discussed a diverse field of subjects: vasculitis, osteoporosis, liver disease, pregnancy & rheumatic disease, pediatric rheumatology, seronegatives & psoriatics, rheumatoid arthritis & lupus nephritis.

Liver Disease
Sidney Barritt, MD, MSCR, associate professor of medicine and director of the University of North Carolina Liver Center, Chapel Hill, gave a talk titled Liver Disease for the Rheumatologist. Dr. Barritt noted that nonalcoholic fatty liver disease (NAFLD) is very common and that up to one in three Americans may have evidence of hepatic steatosis. This is particularly important to note for patients with psoriasis and psoriatic arthritis, because both conditions are associated with metabolic syndrome and NAFLD is, in turn, associated with increased psoriasis severity.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersPediatric ConditionsVasculitis Tagged with:ACR Convergence 2020liver diseasemeeting reportsOsteoporosisPediatricpregnancyVasculitis

Related Articles

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

    Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

    October 10, 2016

    The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

    State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment

    March 19, 2019

    CHICAGO—Held during the 2018 ACR/ARHP Annual Meeting, the ACR Review Course covered a wide range of topics for rheumatologists—from advances in pain and rheumatic disease management to the intersection of rheumatology and neurology. Session speakers shared insights, as well as state-of-the-art approaches to diagnosis, management and treatment. Inflammatory Myopathies Julie J. Paik, MD, MHS, assistant…

    Lupus Nephritis: Understanding the Paradigm for Treatment

    June 16, 2020

    ACR BEYOND LIVE—Among patients with systemic lupus erythematosus (SLE), lupus nephritis remains one of the leading causes of mortality, and patients with both SLE and end-stage renal disease demonstrate standardized mortality ratios higher than 60 times that of patients with SLE who have normal kidney function.1 Although the ACR Guidelines for Screening, Treatment, and Management…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences